September FDA news in review


Welcome to the first installment of "FDA News in Review," where each month we'll take a look at the agency's latest decision, approvals, warnings and recalls. We hope this feature will help you keep up on FDA trends--and catch up on stories you may have missed.

One of the top stories out of the FDA this month was the agency's push to fill 1,300 new positions. The new hires include chemists, biologists and microbiologists, many of whom will be assigned to the CDER. Overall, the agency is increasing its workforce by about 10 percent. And while the FDA was light on approvals this month, it was certainly busy monitoring drug safety. The agency announced that it will now release a quarterly list of drugs under investigation due to adverse events. The nature of the complaints will be included in the report, but the number of complaints won't be.

What's new at the FDA

  • FDA on hiring binge to fill research ranks
  • FDA staffing push yields 1,300 hires
  • Waxman attacks FDA preemption rule
  • Biotech animals focus of regulatory review

FDA Approvals

  • Nasacort approved in 2- to 5-year-olds
  • Three new therapies approved by the FDA
  • FDA grants Gardasil two new indications

FDA Decisions

  • FDA again delays prasugrel decision
  • Panel backs Pfizer's Fablyn, with caution
  • Introgen shares plunge on BLA rejection
  • FDA delays Roche's blockbuster Actemra

Safety, Warnings & Recalls

  • FDA names 20 drugs in safety probes
  • Tarceva linked with two patient deaths
  • FDA halts Ranbaxy India imports
  • FDA orders tougher warnings on TNF drugs

September FDA news in review

Suggested Articles

FDA officials say Novartis took too long to launch a formal probe into allegations of Zolgensma data manipulation.

Should Johnson & Johnson owe billions to fix Oklahoma's opioid crisis? After weeks of trial testimony, a judge will have his say Monday afternoon.

After Endo and Allergan agreed to settle with two Ohio counties on opioid charges this week, the state’s AG has a message: You’re not off the hook.